Multiple Sclerosis
COVID-19 information
We appreciate the current situation regarding COVID-19 is worrying for our patients with Multiple Sclerosis. We have written to patients with guidance relevant to the particular drug regime and copies of the letters are below for general information.
You can find links to these letters here:
- Beta Interferons (Rebif, Betaferon, Plegridy, Avonex)
- Glatiramer Acetate (Brabio, Copaxone)
- Teriflunamide (Aubagio)
- Fingolimod (Gilenya)
- Natalizumab (Tysabri)
- Dimethyl fumarate (Tecfidera)
- Ocrelizumab (Ocrevus)
- Alemtuzumab (Lemtrada)
- Cladribine (Mavenclad)
- Further advice on Cladribine
We hope that you find this information reassuring at this difficult time and we will continue to keep you up to date as things change.
This department provides a comprehensive inpatient out patient and day case service to people with multiple sclerosis and allied conditions - such as Neuromyelitis Optica.
We have a team of consultants interested in multiple sclerosis and one with a neurological disability interest. There is also an excellent team of MS Specialist nurses.
There are clinics both in Sheffield and in some of our linked District General hospitals. Nurse led clinics are provided across the region with a weekly relapse clinic in Sheffield. A wide variety of disease modyfying treatments are also provided on an outpatiet or day case basis, if appropriate.
The service is supported by excellent in patient, day patient and diagnostic radiology and neurophysiology services. The team is also involved in patient and health professional education and highly active in research, both clinical trials and through links with basic science researchers.
Referral addressMultiple Sclerosis Clinic, Clinic timesWednesday morning, |
|